BioNTech’s (BNTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BioNTech (NASDAQ:BNTXFree Report) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $113.00 price objective on the stock.

Other equities research analysts have also issued research reports about the stock. UBS Group lowered their target price on shares of BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a report on Wednesday, March 27th. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group restated a buy rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. BMO Capital Markets lowered their target price on shares of BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a report on Tuesday, May 7th. Finally, Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an inline rating and a $100.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of Hold and a consensus price target of $111.70.

View Our Latest Analysis on BNTX

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $96.00 on Monday. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The stock has a market capitalization of $22.82 billion, a P/E ratio of 192.00 and a beta of 0.27. The firm has a fifty day simple moving average of $92.78 and a two-hundred day simple moving average of $95.83. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTXGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The business had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. On average, analysts expect that BioNTech will post -2.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of BNTX. Harding Loevner LP purchased a new stake in BioNTech during the fourth quarter valued at approximately $410,984,000. Baillie Gifford & Co. lifted its position in BioNTech by 15.5% during the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock valued at $934,612,000 after acquiring an additional 1,152,541 shares during the last quarter. Clearbridge Investments LLC lifted its position in BioNTech by 41.6% during the third quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock valued at $52,595,000 after acquiring an additional 142,344 shares during the last quarter. Primecap Management Co. CA lifted its position in BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in BioNTech by 43.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after acquiring an additional 127,951 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Articles

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.